TARA

Protara Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 4/10
  • Value↑ 5/10
Protara Therapeutics sales and earnings growth
TARA Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 19.16%
  • FCF Y/Y↓ -56.64%
Protara Therapeutics gross and profit margin trends
TARA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -104.14%
Protara Therapeutics net debt vs free cash flow
TARA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Protara Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks